Prediction of Clinically Significant Prostate Cancer Using Multiparametric MRI, Biparametric MRI, and Clinical Parameters
Urologia Internationalis · 2024
DOI: 10.1159/000541152 ↗Kurz gefasst
Fachartikel in der Zeitschrift Urologia Internationalis, 2024. Verfasst von Maximilian Oberneder und 8 weiteren Autor:innen. Beteiligte Einrichtung: Urologische Klinik München-Planegg, Planegg, Germany. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Multiparametric Magnetic Resonance Imaging, Magnetic Resonance Imaging. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben.
Abstract (Originalsprache)
Introduction
Multiparametric MRI (mpMRI) is gold standard for the primary diagnostic work-up of clinically significant prostate cancer (csPCa). The aim of this study was to assess the benefit of the perfusion sequence and the non-inferiority of an MRI without contrast administration (bpMRI) compared to mpMRI while taking clinical parameters into account.
Methods
In this retrospective, non-interventional study we examined MRI data from 355 biopsy-naïve patients, performed on a 3T MRI system, evaluated by a board-certified radiologist with over 10 years of experience with subsequent mpMRI-TRUS fusion biopsy.
Discussion
Only 16/355 (4.5%) patients benefited from dynamic contrast enhanced. In only 3/355 (0.8%) patients, csPCa would have been missed in bpMRI. BpMRI provided sensitivity and specificity (81.4%; 79.4%) comparable to mpMRI (75.2%; 81.8%). Additionally, bpMRI and mpMRI were independent predictors for the presence of csPCa, individually (OR: 15.36; p < 0.001 vs. 12.15; p = 0.006) and after accounting for established influencing factors (OR: 12.81; p < 0.001 vs. 6.50; p = 0.012). When clinical parameters were considered, a more balanced diagnostic performance between sensitivity and specificity was found for mpMRI and bpMRI. Overall, PSA density showed the highest diagnostic performance (area under the curve = 0.81) for the detection of csPCa.
Conclusion
The premise of the study was confirmed. Therefore, bpMRI should be adopted as soon as existing limitations have been lifted by prospective multi-reader studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Urologische Klinik München-Planegg, Planegg, Germany.
- RH Diagnostik und Therapie GmbH, Munich, Germany.
- Conradia Radiologie, Munich, Germany.
- Ihre-Radiologen.de MVZ GmbH, Berlin, Germany.
- Pathologie München-Nord, Munich, Germany.
- Radiology Department, Klinikum rechts der Isar der TUM, Munich, Germany.
Zitieren
APA
Oberneder, M., Henzler, T., Kriegmair, M., Vag, T., Roethke, M., Siegert, S., Lang, R., Lenk, J., & Gawlitza, J. (2024). Prediction of Clinically Significant Prostate Cancer Using Multiparametric MRI, Biparametric MRI, and Clinical Parameters. Urologia Internationalis. https://doi.org/10.1159/000541152
Vancouver
Oberneder M, Henzler T, Kriegmair M, Vag T, Roethke M, Siegert S, et al. Prediction of Clinically Significant Prostate Cancer Using Multiparametric MRI, Biparametric MRI, and Clinical Parameters. Urologia Internationalis. 2024. doi:10.1159/000541152
BibTeX
@article{Oberneder2024,
author = {Oberneder, Maximilian and Henzler, Thomas and Kriegmair, Martin and Vag, Tibor and Roethke, Matthias and Siegert, Sabine and Lang, Roland and Lenk, Julia and Gawlitza, Joshua},
title = {Prediction of Clinically Significant Prostate Cancer Using Multiparametric MRI, Biparametric MRI, and Clinical Parameters},
journal = {Urologia Internationalis},
year = {2024},
doi = {10.1159/000541152}
}
EUVIMED